BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles.

被引：0

作者：

Xu, Jiangcheng ^{[1
]}

Liu, Yang ^{[1
]}

Wang, Jing ^{[1
]}

Fan, Fei ^{[1
]}

Gu, Haitao ^{[1
]}

Zhang, Lanxin ^{[1
]}

Wang, Jun ^{[1
]}

Song, Ding ^{[1
]}

Guo, Ailong ^{[1
]}

Zhang, Hongjuan ^{[1
]}

Su, Kaixuan ^{[1
]}

Su, Jiaojiao ^{[1
]}

Li, Lijuan ^{[1
]}

Cai, Jingmei ^{[1
]}

Zhang, Aihong ^{[1
]}

Liu, Jiawang ^{[1
]}

Lee, Kyoungwoo ^{[1
]}

机构：

[1] Beijing Hanmi Res Ctr, Beijing, Peoples R China

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5605

引用

页数：1

共 50 条

[41] Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys
Wang, Jing
Dong, Tiantian
Gong, Xinjiang
Li, Deli
Sun, Joanne
Luo, Yi
Wu, Huazhang
INTERNATIONAL JOURNAL OF TOXICOLOGY, 2024, 43 (03) : 291 - 300
[42] YH32364 (ABL104), A NOVEL EGFR/4-1BB BISPECIFIC ANTIBODY EXHIBITS POTENT ANTITUMOR EFFICACY WITH AN EXCELLENT SAFETY PROFILE
Lee, Eunjung
Chung, Hyejin
Lee, Yangsoon
Park, Young Bong
Lee, Eun-Jung
Koo, Hyunmo
Ju, Mikyeong
Park, Ju Young
Ahn, Sujin
Kim, Junhwan
Park, Kyeongsu
Son, Wonjun
Eom, Jaehyun
Lee, Hanbyul
Jung, Jaeho
Won, Jonghwa
Oh, Se-Woong
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1100 - A1100
[43] A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
Koopmans, Iris
Hendriks, Djoke
Samplonius, Douwe F.
van Ginkel, Robert J.
Heskamp, Sandra
Wierstra, Peter J.
Bremer, Edwin
Helfrich, Wijnand
ONCOIMMUNOLOGY, 2018, 7 (08):
[44] A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
Koopmans, Iris
Samplonius, Douwe F.
van Ginkel, Robert J.
Wierstra, Peter J.
Heskamp, Sandra
Bremer, Edwin
Helfrich, Wijnand
CANCER RESEARCH, 2018, 78 (13)
[45] Batf3+DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
Ziblat, Andrea
Horton, Brendan L.
Higgs, Emily F.
Hatogai, Ken
Martinez, Anna
Shapiro, Jason W.
Kim, Danny E. C.
Zha, Yuanyuan
Sweis, Randy F.
Gajewski, Thomas F.
CELL REPORTS, 2024, 43 (05):
[46] Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation
Zhang, Chenxing
Liu, Jiaxin
Gu, Tiejun
Meng, Xiangyu
Cai, Xiaoyi
Zhang, Jinfeng
Chen, Yan
Zhang, Daguang
Wu, Yongge
BREAST CANCER RESEARCH AND TREATMENT, 2025, : 637 - 648
[47] Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors
Xue, Junli
Zhang, Yan
Hu, Xudong
Zhao, Wei
Sun, Yuping
Li, Qun
Jin, Xiaoying
Xue, Liqiong
Ge, Xiaoxiao
Lin, Fengjuan
Tang, Wenbo
Zhou, Jiuli
Guo, Ye
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] PHASE I SAFETY AND PRELIMINARY EFFICACY OF PM8002 IN SUBJECTS WITH ADVANCED SOLID TUMORS, A BISPECIFIC ANTIBODY TARGETING PD-L1 AND VEGF-A
Guo, Ye
Luo, Suxia
Qin, Yanru
Yin, Yongmei
Li, Guiling
Wang, Jingfen
Li, Yongsheng
Guo, Jun
Zhang, Feng
Huang, Yi
Luo, Hong
Lv, Dongqing
Ying, Cheng
Wang, Chunyan
Chou, Chuan-Chu
Gong, Chundan
Chang, Ruixia
Liu, Jing
Hu, Guoqiang
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A758 - A758
[49] Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
Liu, Guizhong
Luo, Peter
FRONTIERS IN IMMUNOLOGY, 2023, 14
[50] Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody
Dahlman, Anna
Nelson, Michelle
Bannink, Jeannette
Johnson, Starrla
Werchau, Doreen
Nilsson, Anneli
Ljung, Lill
Blahnik-Fagan, Gabriele
Bader, Robert
Deronic, Adnan
Ellmark, Peter
Askmyr, Maria
Hernandez-Hoyos, Gabriela
McMahan, Cathy
Fritzell, Sara
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →